Theodore Logan

  • 6025 Citations
  • 35 h-Index
1976 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Theodore Logan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
Renal Cell Carcinoma Medicine & Life Sciences
Melanoma Medicine & Life Sciences
Interleukin-2 Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Safety Medicine & Life Sciences
Cytokines Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

NIH Grants 1976 2009

GENERAL CLINICAL RESEARCH CENTER

Wilkes, D., Crabb, D., Rex, D., Einhorn, L., Zipes, D., Benson, M., Moe, S., Abonour, R., Farlow, M., Miller, K., Loehrer, P., Cripe, L., Peacock, M., DiMeglio, L., Econs, M., Spinola, S., de Cordon, K., Denne, S., Kwo, P., Agarwal, R., Considine, R., Poindexter, B., Stevens, J., Kraus, M., Chalasani, N., Robertson, M., Logan, T., Croop, J., Groh, W., Robertson, M., Hannon, T., Wojcieszek, J., Considine, R., Mather, K., Chalasani, N., Flockhart, D. A., Foroud, T., Desta, Z., Benson, M., Kareken, D., Poindexter, B., Friedman, A., Gupta, S., Schneider, B., Carpenter, J., Steiner, S., Storniolo, A. M., Cripe, L., Murphy, M., Molleston, J., Hui, S., Von Ah, D., Logan, T., Sawada, S., Fineberg, S. E., Edmondson, J. W., Lumeng, L., O'Connor, K., Clark, C. M., Maxwell, D., Scott, P., Prystowsky, E., Hoffman, R., Brater, C. D., Brandt, I., Bradley, J., Vinicor, F., Williams, S., Weir, C., Heger, J., Thomasson, H., Manolagas, S., Duckworth, W., MacLaren, N., Mohler, E., Baker, J., Vargo, D., Lehman, G., Einhorm, L., Luft, F., Scheller, C., Rudy, D., Merritt, D. H., Kleit, S., Williams, D., Wheeler, M., Twigg, H., Weinberger, M., Wheat, L. J., Holden, R., Rawl, S., Smith, F. O., Shankar, R., Kirkman, S. U. E., Richardson, J., Pratt, J. H., Rodriguez, H., Hall, S., McDougle, C., Brater, D. C., Dropco, E., Krause, M., Baker, S., Wilensky, R., Hamburger, R., Jakacki, R., Oconnor, S., Rink, R., Biller, J., Prince, M., Klaunig, J., Reed, T. E., Harris, A., Myers, S., Jackson, R., Jindal, R., Haehner, B., Johnston, C. C., Black, J., McCaskill-Steve, W., Clark, C., Roos, K., Batiuk, T., Brady, M., Oconner, S., Keck, J., Brashear, A., Timmerman, R., Goldmna, M., Mohler, E. R., Guare, J., Frank, M., Siemers, E., Dropcho, E. J., Davidson, D., Pompili, V., Patrick Loehrer, M. D., Gumbiner, B., Michael Frank, M. D., Wheat, L. J., O'Connor, S., Dusick, A., Ernst, J., Sowinski, K., Batiuk, T., Rushing, D., Stout, J., Bangs, M., Sokol, G., Lemons, J., Gorski, J. C., Johnson, R., Sweeney, C., Dennis Chua, A., Dube, M., Galinsky, R. E., Steinberg, H., Pescovitz, M. D., Twigg, H., Fife, K. H., O'Connor, S. J., Tisdale, J. E., Vik, T., Govani, M., Gardner, T. W., Blekher, T., Kays, M., Johnston, C., Howenstine, M., Dusick, A., Yaqub, M., Kreher, N., Morris, E., Posey, D., Nebesio, T., Ragg, S., Kowolik, M., Ellett, M., Shankar, S., Walvoord, E., Shore, C., Deeg, M., Matei, D., Tisdale, J. E., Bruno, A., Knox, K., Stout, J., Blekher, T., Saifullah, A., Jin, Y. A. N., Griest, A., Nurnberger, J., Hathaway, D., Voelker, J., Abel, L., Faust, H., Brater, C., Garcia, J. O. E., Garvey, T., Johnston, C. C., Fergusson, J., O'Connor, S., Greist, A., Shapiro, A. M. Y., Eigen, H., Roth, B. J., Pescovitz, O., Lemons, J., Pescovitz, M., Rickard, K., Christian, J., Sokol, G., Bradley, J. D., Steinberg, H., Freidenberg, G., Wheat, J., Fife, K., Gordon, M., Pratt, H., Mannix, E., Sledge, G., Sandler, A., Baron, A., Leitch, C. & Goldman, M.

National Institutes of Health

12/1/7611/30/09

Project: Research project

salmon calcitonin
Haemophilus ducreyi
Amyloidosis
Osteoporotic Fractures
Osteoporosis

Publications 1983 2019

  • 6025 Citations
  • 35 h-Index
  • 68 Article
  • 1 Letter
1 Citation (Scopus)

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Voss, M. H., Bhatt, R. S., Vogelzang, N. J., Fishman, M., Alter, R. S., Rini, B. I., Beck, J. T., Joshi, M., Hauke, R., Atkins, M. B., Burgess, E., Logan, T., Shaffer, D., Parikh, R., Moazzam, N., Zhang, X., Glasser, C., Sherman, M. L. & Plimack, E. R., Jan 1 2019, In : Cancer.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Placebos
Disease-Free Survival
axitinib
Human ALK1-Fc fusion protein
5 Citations (Scopus)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Clark, J. I., Singh, J., Ernstoff, M. S., Lao, C. D., Flaherty, L. E., Logan, T., Curti, B., Agarwala, S. S., Taback, B., Cranmer, L., Lutzky, J., Luna, T. L., Aung, S. & Lawson, D. H., Jul 27 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 76.

Research output: Contribution to journalArticle

Interleukin-2
Melanoma
Mutation
Antigen Presentation
Neoplasm Antigens
1 Citation (Scopus)

NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma

Tarhini, A. A., Frankel, P., Ruel, C., Ernstoff, M. S., Kuzel, T. M., Logan, T., Khushalani, N. I., Tawbi, H. A., Margolin, K. A., Awasthi, S., Butterfield, L. H., McDermott, D., Chen, A., Lara, P. N. & Kirkwood, J. M., Jan 1 2018, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

Interleukin-2
Melanoma
Vascular Endothelial Growth Factor A
Confidence Intervals
Disease-Free Survival
109 Citations (Scopus)

Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma

Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., Logan, T., Hauschild, A., Lebbé, C., Chen, L., Kim, J. J., Gansert, J., Andtbacka, R. H. I. & Kaufman, H. L., Jun 10 2018, In : Journal of Clinical Oncology. 36, 17, p. 1658-1667 10 p.

Research output: Contribution to journalArticle

Melanoma
Safety
ipilimumab
Oncolytic Viruses
Chills
5 Citations (Scopus)

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: Data from the PROCLAIMSM registry

Curti, B., Daniels, G. A., McDermott, D. F., Clark, J. I., Kaufman, H. L., Logan, T., Singh, J., Kaur, M., Luna, T. L., Gregory, N., Morse, M. A., Wong, M. K. K. & Dutcher, J. P., Dec 19 2017, In : Journal for ImmunoTherapy of Cancer. 5, 1, 102.

Research output: Contribution to journalArticle

Interleukin-2
Registries
Survival
Neoplasms
Therapeutics